Anthropic filed for an IPO on Monday with disclosures that strike a more cautious tone about its drug discovery ambitions than recent public statements by CEO Dario Amodei, according to Wired.
The filing acknowledges the company “need[s] first-hand experience doing scientific research and drug discovery” and that its life sciences activities will require “activities outside our historical experience as a software and research organization,” including handling hazardous materials, operating laboratory equipment and navigating pharmaceutical regulations.
This contrasts with Amodei’s August prediction on X that AI will make it possible to cure most human diseases in the next five to 10 years and deliver a “deluge of AI-accelerated drugs.” Two years ago, he wrote he was “open” to the idea that AI could compress a thousand years of biological progress into five to 10 years.
The IPO filing also revised language about an enzyme discovery Anthropic promoted in September as “Crispr-like.” The company now says the enzyme “might have the potential to be developed into a novel biotechnology tool, perhaps for gene editing.” Researchers told Wired they were skeptical of the discovery’s value, and one scientist who had been studying the same enzymes questioned whether Claude used his research, though Anthropic said neither its model nor molecular biology team would have had access to that material.
The filing indicates Anthropic now sees biotech discovery as a core business activity rather than merely providing AI tools to outside researchers. The company notes that even AI-assisted discoveries face the standard drug development timeline requiring test tube research, animal studies and human trials.
While the filing still claims AI can “profoundly accelerate the rate of progress in biology and medicine” and compress “decades of scientific progress into years,” it frames these as possibilities rather than near-term certainties.